Zealand Pharma ASZLDPF 62 Piotroski F-Score is 8 as of Jun. 25, 2026, which is 100% above its 10-year median of 4.00. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $1,948.90 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,342 Biotechnology companies, Zealand Pharma AS ranks better than 99.33% on this metric.
Good Sign:
Piotroski F-Score is 8, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Zealand Pharma AS has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Zealand Pharma AS's Piotroski F-Score or its related term are showing as below:
ZLDPF'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 4 Max: 8
Current: 8
During the past 13 years, the highest Piotroski F-Score of Zealand Pharma AS was 8. The lowest was 1. And the median was 4.
Zealand Pharma AS (OTCPK:ZLDPF) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Zealand Pharma AS Piotroski F-Score Related Terms
Zealand Pharma AS Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZLDPF vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Zealand Pharma AS's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Zealand Pharma AS's current Net Income (TTM) was 987.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Zealand Pharma AS's return on assets of this year was 0.74648691. Zealand Pharma AS's return on assets of last year was -0.32760536.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Zealand Pharma AS's gearing of this year was 0.02592034. Zealand Pharma AS's gearing of last year was 0.04509557.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Zealand Pharma AS's current ratio of this year was 37.17352409. Zealand Pharma AS's current ratio of last year was 25.10304893.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Zealand Pharma AS's number of shares in issue this year was 70.609. Zealand Pharma AS's number of shares in issue last year was 70.675.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Zealand Pharma AS's gross margin of this year was 0.99995591. Zealand Pharma AS's gross margin of last year was 0.94495756.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Zealand Pharma AS's asset turnover of this year was 1.08075732. Zealand Pharma AS's asset turnover of last year was 0.01532303.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
0
+
1
+
1
+
1
+
1
+
1
=
8
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Zealand Pharma AS has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
Zealand Pharma AS (ZLDPF) has a Piotroski F-Score of 8 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zealand Pharma AS and its competitors. This is 100% above median its historical median of 4.00. Over the past decade, Zealand Pharma AS's Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Zealand Pharma AS ranks #9 out of 1342 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Zealand Pharma AS's Piotroski F-Score too high?
Zealand Pharma AS's current Piotroski F-Score of 8 is 100% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Zealand Pharma AS's value of 8 is 166.7% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #9 out of 1342 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #9 out of 1342 companies for Piotroski F-Score. This places Zealand Pharma AS in the top 1% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Zealand Pharma AS's value of 8 is 166.7% above this benchmark. Historically, Zealand Pharma AS's own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Zealand Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current Piotroski F-Score of 8 is 166.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Piotroski F-Score is 8, which is 100% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,948.90, compared to a current price of $42.89 — trading 97.8% below its estimated fair value. The current Piotroski F-Score is 8, which is 100% above median its 10-year median of 4.00 and 166.7% above the Biotechnology industry median of 3.00. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Piotroski F-Score is 8 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $42.89 is trading 97.8% below its estimated GF Value™ of $1,948.90.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
Piotroski F-Score: 8 (100% above median its 10-year median of 4.00)
GF Value™: $1,948.90 vs. price of $42.89 (97.8% below fair value)
Industry Position: 166.7% above the Biotechnology median (#9 of 1342)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score
Get the complete analysis for ZLDPF
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
